178 related articles for article (PubMed ID: 32592321)
21. Germline mutations and somatic inactivation of TRIM28 in Wilms tumour.
Halliday BJ; Fukuzawa R; Markie DM; Grundy RG; Ludgate JL; Black MA; Skeen JE; Weeks RJ; Catchpoole DR; Roberts AGK; Reeve AE; Morison IM
PLoS Genet; 2018 Jun; 14(6):e1007399. PubMed ID: 29912901
[TBL] [Abstract][Full Text] [Related]
22. Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.
Ortiz MV; Ahmed S; Burns M; Henssen AG; Hollmann TJ; MacArthur I; Gunasekera S; Gaewsky L; Bradwin G; Ryan J; Letai A; He Y; Naranjo A; Chi YY; LaQuaglia M; Heaton T; Cifani P; Dome JS; Gadd S; Perlman E; Mullen E; Steen H; Kentsis A
JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391345
[TBL] [Abstract][Full Text] [Related]
23. WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor.
Cardoso LC; De Souza KR; De O Reis AH; Andrade RC; Britto AC; De Lima MA; Dos Santos AC; De Faria PS; Ferman S; Seuánez HN; Vargas FR
Oncol Rep; 2013 Jan; 29(1):315-20. PubMed ID: 23117548
[TBL] [Abstract][Full Text] [Related]
24. Novel familial WT1 read-through mutation associated with Wilms tumor and slow progressive nephropathy.
Zirn B; Wittmann S; Gessler M
Am J Kidney Dis; 2005 Jun; 45(6):1100-4. PubMed ID: 15957141
[TBL] [Abstract][Full Text] [Related]
25. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ;
Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316
[TBL] [Abstract][Full Text] [Related]
26. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.
Ruteshouser EC; Robinson SM; Huff V
Genes Chromosomes Cancer; 2008 Jun; 47(6):461-70. PubMed ID: 18311776
[TBL] [Abstract][Full Text] [Related]
27. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
[TBL] [Abstract][Full Text] [Related]
28. Erythropoietin levels in patients with Wilms' tumor. Follow-up evaluation.
Murphy GP; Allen JE; Staubitz WJ; Sinks LF; Mirand EA
N Y State J Med; 1972 Feb; 72(4):487-9. PubMed ID: 4334449
[No Abstract] [Full Text] [Related]
29. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
30. Loss of heterozygosity in Wilms' tumour involves two distinct regions of chromosome 11.
Wadey RB; Pal N; Buckle B; Yeomans E; Pritchard J; Cowell JK
Oncogene; 1990 Jun; 5(6):901-7. PubMed ID: 2163053
[TBL] [Abstract][Full Text] [Related]
31. Genetic mosaicism in normal tissues of Wilms' tumour patients.
Chao LY; Huff V; Tomlinson G; Riccardi VM; Strong LC; Saunders GF
Nat Genet; 1993 Feb; 3(2):127-31. PubMed ID: 8388768
[TBL] [Abstract][Full Text] [Related]
32. Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood.
Charlton J; Williams RD; Weeks M; Sebire NJ; Popov S; Vujanic G; Mifsud W; Alcaide-German M; Butcher LM; Beck S; Pritchard-Jones K
Genome Biol; 2014 Aug; 15(8):434. PubMed ID: 25134821
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the p53 gene by PCR-SSCP in ten cases of Wilms' tumor.
Defavery R; Lemos JA; Kashima S; Bernardes JE; Scridelli CA; Covas DT; Tone LG
Sao Paulo Med J; 2000 Mar; 118(2):49-52. PubMed ID: 10772697
[TBL] [Abstract][Full Text] [Related]
34. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
[TBL] [Abstract][Full Text] [Related]
35. Convergent evolution of 11p allelic loss in multifocal Wilms tumors arising in WT1 mutation carriers.
Valind A; Wessman S; Pal N; Karlsson J; Jonson T; Sandstedt B; Gisselsson D
Pediatr Blood Cancer; 2018 Nov; 65(11):e27301. PubMed ID: 29968962
[TBL] [Abstract][Full Text] [Related]
36. Genotype/phenotype correlations in Wilms' tumor.
Huff V
Med Pediatr Oncol; 1996 Nov; 27(5):408-14. PubMed ID: 8827067
[TBL] [Abstract][Full Text] [Related]
37. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
38. Clinical features and long-term outcomes of bilateral Wilms tumor treated with Taiwan Pediatric Oncology Group protocols: A single center report.
Chen SH; Hung IJ; Yang CP; Jaing TH; Wang CJ; Hsueh C; Lai JY
Asia Pac J Clin Oncol; 2016 Sep; 12(3):300-7. PubMed ID: 27230630
[TBL] [Abstract][Full Text] [Related]
39. Fanconi anemia gene mutations are not involved in sporadic Wilms tumor.
Adank MA; Segers H; van Mil SE; van Helsdingen YM; Ameziane N; van den Ouweland AM; Wagner A; Meijers-Heijboer H; Kool M; de Kraker J; Waisfisz Q; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2010 Oct; 55(4):742-4. PubMed ID: 20589654
[TBL] [Abstract][Full Text] [Related]
40. WT1 exon 1 deletion/insertion mutations in Wilms tumor patients, associated with di- and trinucleotide repeats and deletion hotspot consensus sequences.
Huff V; Jaffe N; Saunders GF; Strong LC; Villalba F; Ruteshouser EC
Am J Hum Genet; 1995 Jan; 56(1):84-90. PubMed ID: 7825606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
